zbh-8k_20180402.htm

0001564590-18-007785.txt : 20180406 0001564590-18-007785.hdr.sgml : 20180406 20180406170022 ACCESSION NUMBER: 0001564590-18-007785 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20180406 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20180406 DATE AS OF CHANGE: 20180406 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ZIMMER BIOMET HOLDINGS, INC. CENTRAL INDEX KEY: 0001136869 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 134151777 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16407 FILM NUMBER: 18743835 BUSINESS ADDRESS: STREET 1: 345 EAST MAIN STREET CITY: WARSAW STATE: IN ZIP: 46580 BUSINESS PHONE: 5742676131 MAIL ADDRESS: STREET 1: 345 EAST MAIN STREET CITY: WARSAW STATE: IN ZIP: 46580 FORMER COMPANY: FORMER CONFORMED NAME: ZIMMER HOLDINGS INC DATE OF NAME CHANGE: 20010315 8-K 1 zbh-8k_20180402.htm 8-K zbh-8k_20180402.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 6, 2018

ZIMMER BIOMET HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-16407	13-4151777
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

345 East Main Street

Warsaw, Indiana 46580

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (574) 267-6131

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD Disclosure.

As discussed in Zimmer Biomet Holdings, Inc.’s (the “Company,” “we” or “us”) Annual Report on Form 10-K for the year ended December 31, 2017, effective January 1, 2018, we adopted Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”) and Accounting Standards Update No. 2017-07, Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost (“ASU 2017-07”). We are furnishing this Form 8-K under Regulation FD to supplementally present, for informational purposes only, certain previously-reported financial information on an adjusted basis consistent with the new standards. This adjusted financial information is also being made available on our investor relations website. Beginning with the quarter ended March 31, 2018, our financial information will reflect the adoption of these standards, with prior periods adjusted accordingly.

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09. This ASU provides a five-step model for revenue recognition that all industries will apply to recognize revenue when a customer obtains control of a good or service. For us, the principal impact of the standard is the reclassification of certain immaterial costs from selling, general and administrative expense to net sales, which results in a reduction of net sales, but has no impact on operating profit. Under this ASU, entities are permitted to apply the standard and related amendments either retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the ASU recognized at the date of initial application. We elected to adopt this new standard using the retrospective method, which results in us restating prior reporting periods presented.

In March 2017, the FASB issued ASU 2017-07. This ASU requires us to report the service cost component of pensions in the same location as other compensation costs arising from services rendered by the pertinent employees during the period. We are required to report the other components of net benefit costs in Other income (expense) in the statement of earnings. This ASU must be applied retrospectively for the presentation of the service cost component and the other components of net periodic pension cost in the statement of earnings and prospectively, on and after January 1, 2018, for the capitalization of the service cost component of net periodic pension cost in assets. Therefore, our prior period operating and non-operating expenses are impacted by offsetting amounts.

The application of the new standards only changes the financial statement line items in which we present certain costs. Accordingly, there has been no change to our reported or adjusted net income.

Exhibit 99.1 to this Current Report on Form 8-K presents, for informational purposes only, supplemental financial information for the years ended December 31, 2017 and 2016, as well as each quarterly period in those years, on an adjusted basis consistent with the new standards. Additional information regarding the impact of the adoption of the new standards and related disclosures will be included in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 and in subsequent filings that we make with the Securities and Exchange Commission.

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits

EXHIBIT INDEX
Exhibit No.		Description
99.1		Supplemental Financial Information of Zimmer Biomet Holdings, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 6, 2018	ZIMMER BIOMET HOLDINGS, INC.

	By:	/s/ Tony W. Collins
	Name:	Tony W. Collins
	Title:	Vice President, Corporate Controller and Chief Accounting Officer

EX-99.1 2 zbh-ex991_14.htm EX-99.1 zbh-ex991_14.htm

345 E. Main St.
Warsaw, IN 46580
www.zimmerbiomet.com	Exhibit 99.1

Media	Investors
Monica Kendrick	Cole Lannum
(574) 372-4989	(574) 371-9480
Monica.Kendrick@ZimmerBiomet.com	Cole.Lannum@ZimmerBiomet.com
	Derek Davis (574) 372-4250 Derek.Davis@ZimmerBiomet.com
	Barbara Goslee
	(574) 371-9449
	Barb.Goslee@ZimmerBiomet.com

The following supplemental financial information presents, for informational purposes only, certain previously-reported financial information of Zimmer Biomet Holdings, Inc. (the “Company”), as adjusted to reflect the adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”) and Accounting Standards Update No. 2017-07, Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost (“ASU 2017-07”).

Certain of the previously-reported financial information consisted of reconciliations of financial measures not calculated in accordance with U.S. generally accepted accounting principles (“GAAP”) to the most directly comparable GAAP measures. These reconciliations are presented below, updated to utilize the revised GAAP financial measures, which have been adjusted to reflect the adoption of ASU 2014-09 and ASU 2017-07, in the reconciliations. The non-GAAP financial measures may not be comparable to similar measures reported by other companies and should be considered in addition to, and not as a substitute for, or superior to, other measures prepared in accordance with GAAP.

Revised gross profit, revised gross margin, revised operating profit (loss) and revised operating profit (loss) margin (in each case, revised to reflect the adoption of ASU 2014-09 and ASU

2017-07) are presented on a GAAP basis and on an adjusted basis. Adjusted revised gross profit and adjusted revised gross margin exclude the effects of inventory step-up, other inventory and manufacturing-related charges and intangible asset amortization. Adjusted revised operating profit and adjusted revised operating profit margin exclude the effects of inventory step-up, other inventory and manufacturing-related charges, intangible asset amortization, goodwill impairment and special items.

Management of the Company uses these non-GAAP financial measures internally to evaluate the performance of the business and believes they are useful measures that provide meaningful supplemental information to investors to consider when evaluating the performance of the Company. Management believes these measures offer the ability to make period-to-period comparisons that are not impacted by certain items that can cause dramatic changes in reported operating results, to perform trend analysis, to better identify operating trends that may otherwise be masked or distorted by these types of items and to provide additional transparency of certain items. In addition, certain of these non-GAAP financial measures are used as performance metrics in the Company's incentive compensation programs.

Certain amounts in the 2016 and 2017 net sales by product categories have been reclassified to conform to the 2018 presentation.

ZIMMER BIOMET HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE THREE MONTHS ENDED MARCH 31, 2016
(in millions, except per share amounts, unaudited)

	As Originally Reported			Adjustments ⁽¹⁾			As Adjusted
Net Sales	$	1,904.0		$	(3.2	)	$	1,900.8
Cost of products sold, excluding intangible asset amortization		640.6			-			640.6
Intangible asset amortization		126.6			-			126.6
Research and development		85.7			-			85.7
Selling, general and administrative		716.9			(2.0	)		714.9
Special items		88.7			-			88.7
Operating expenses		1,658.5			(2.0	)		1,656.5
Operating Profit		245.5			(1.2	)		244.3
Other expense, net		(3.8	)		1.2			(2.6	)
Interest income		1.3			-			1.3
Interest expense		(88.2	)		-			(88.2	)
Earnings before income taxes		154.8			-			154.8
Provision for income taxes		46.1			-			46.1
Net Earnings		108.7			-			108.7
Less: Net Loss attributable to noncontrolling interest		(0.1	)		-			(0.1	)
Net Earnings of Zimmer Biomet Holdings, Inc.	$	108.8		$	-		$	108.8

Earnings Per Common Share
Basic	$	0.54		$	-		$	0.54
Diluted	$	0.54		$	-		$	0.54
Weighted Average Common Shares Outstanding
Basic		200.1			-			200.1
Diluted		202.2			-			202.2


⁽¹⁾ New accounting standard adjustments include a reclassication of certain costs from Selling, general and administrative expenses to Net Sales due to the adoption of ASU 2014-09 and a reclassification of certain components of pension expense from Selling, general and administrative expenses to Other expense, net due to the adoption of ASU 2017-07.

ZIMMER BIOMET HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE THREE MONTHS ENDED JUNE 30, 2016
(in millions, except per share amounts, unaudited)

	As Originally Reported			Adjustments ⁽¹⁾			As Adjusted
Net Sales	$	1,934.0		$	(3.9	)	$	1,930.1
Cost of products sold, excluding intangible asset amortization		640.1			-			640.1
Intangible asset amortization		133.8			-			133.8
Research and development		88.6			-			88.6
Selling, general and administrative		732.0			(2.7	)		729.3
Special items		137.9			-			137.9
Operating expenses		1,732.4			(2.7	)		1,729.7
Operating Profit		201.6			(1.2	)		200.4
Other expense, net		(3.8	)		1.2			(2.6	)
Interest income		0.8			-			0.8
Interest expense		(88.1	)		-			(88.1	)
Earnings before income taxes		110.5			-			110.5
Provision for income taxes		142.2			-			142.2
Net (Loss)		(31.7	)		-			(31.7	)
Less: Net Loss attributable to noncontrolling interest		(0.4	)		-			(0.4	)
Net (Loss) of Zimmer Biomet Holdings, Inc.	$	(31.3	)	$	-		$	(31.3	)

(Loss) Per Common Share
Basic	$	(0.16	)	$	-		$	(0.16	)
Diluted	$	(0.16	)	$	-		$	(0.16	)
Weighted Average Common Shares Outstanding
Basic		199.4			-			199.4
Diluted		199.4			-			199.4


⁽¹⁾ New accounting standard adjustments include a reclassication of certain costs from Selling, general and administrative expenses to Net Sales due to the adoption of ASU 2014-09 and a reclassification of certain components of pension expense from Selling, general and administrative expenses to Other expense, net due to the adoption of ASU 2017-07.

ZIMMER BIOMET HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2016
(in millions, except per share amounts, unaudited)

	As Originally Reported			Adjustments ⁽¹⁾			As Adjusted
Net Sales	$	1,832.8		$	(3.6	)	$	1,829.2
Cost of products sold, excluding intangible asset amortization		479.3			-			479.3
Intangible asset amortization		164.3			-			164.3
Research and development		95.6			-			95.6
Selling, general and administrative		727.7			(2.4	)		725.3
Special items		170.4			-			170.4
Operating expenses		1,637.3			(2.4	)		1,634.9
Operating Profit		195.5			(1.2	)		194.3
Other (expense)/income, net		(1.1	)		1.2			0.1
Interest income		0.6			-			0.6
Interest expense		(91.5	)		-			(91.5	)
Earnings before income taxes		103.5			-			103.5
Provision for income taxes		(54.4	)		-			(54.4	)
Net Earnings		157.9			-			157.9
Less: Net Loss attributable to noncontrolling interest		(0.9	)		-			(0.9	)
Net Earnings of Zimmer Biomet Holdings, Inc.	$	158.8		$	-		$	158.8

Earnings Per Common Share
Basic	$	0.79		$	-		$	0.79
Diluted	$	0.78		$	-		$	0.78
Weighted Average Common Shares Outstanding
Basic		200.1			-			200.1
Diluted		202.9			-			202.9


⁽¹⁾ New accounting standard adjustments include a reclassication of certain costs from Selling, general and administrative expenses to Net Sales due to the adoption of ASU 2014-09 and a reclassification of certain components of pension expense from Selling, general and administrative expenses to Other expense, net due to the adoption of ASU 2017-07.

ZIMMER BIOMET HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE THREE MONTHS ENDED DECEMBER 31, 2016
(in millions, except per share amounts, unaudited)

	As Originally Reported			Adjustments ⁽¹⁾			As Adjusted
Net Sales	$	2,013.1		$	(4.8	)	$	2,008.3
Cost of products sold, excluding intangible asset amortization		621.8			-			621.8
Intangible asset amortization		141.2			-			141.2
Research and development		95.7			-			95.7
Selling, general and administrative		756.3			(3.6	)		752.7
Special items		214.8			-			214.8
Operating expenses		1,829.8			(3.6	)		1,826.2
Operating Profit		183.3			(1.2	)		182.1
Other expense, net		(62.6	)		1.2			(61.4	)
Interest income		0.2			-			0.2
Interest expense		(90.1	)		-			(90.1	)
Earnings before income taxes		30.8			-			30.8
Provision for income taxes		(38.9	)		-			(38.9	)
Net Earnings		69.7			-			69.7
Less: Net Loss attributable to noncontrolling interest		0.1			-			0.1
Net Earnings of Zimmer Biomet Holdings, Inc.	$	69.6		$	-		$	69.6

Earnings Per Common Share
Basic	$	0.35		$	-		$	0.35
Diluted	$	0.34		$	-		$	0.34
Weighted Average Common Shares Outstanding
Basic		200.4			-			200.4
Diluted		202.5			-			202.5


⁽¹⁾ New accounting standard adjustments include a reclassication of certain costs from Selling, general and administrative expenses to Net Sales due to the adoption of ASU 2014-09 and a reclassification of certain components of pension expense from Selling, general and administrative expenses to Other expense, net due to the adoption of ASU 2017-07.

ZIMMER BIOMET HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE YEAR ENDED DECEMBER 31, 2016
(in millions, except per share amounts, unaudited)

	As Originally Reported			Adjustments ⁽¹⁾			As Adjusted
Net Sales	$	7,683.9		$	(15.5	)	$	7,668.4
Cost of products sold, excluding intangible asset amortization		2,381.8			-			2,381.8
Intangible asset amortization		565.9			-			565.9
Research and development		365.6			-			365.6
Selling, general and administrative		2,932.9			(10.7	)		2,922.2
Special items		611.8			-			611.8
Operating expenses		6,858.0			(10.7	)		6,847.3
Operating Profit		825.9			(4.8	)		821.1
Other expense, net		(71.3	)		4.8			(66.5	)
Interest income		2.9			-			2.9
Interest expense		(357.9	)		-			(357.9	)
Earnings before income taxes		399.6			-			399.6
Provision for income taxes		95.0			-			95.0
Net Earnings		304.6			-			304.6
Less: Net Loss attributable to noncontrolling interest		(1.3	)		-			(1.3	)
Net Earnings of Zimmer Biomet Holdings, Inc.	$	305.9		$	-		$	305.9

Earnings Per Common Share
Basic	$	1.53		$	-		$	1.53
Diluted	$	1.51		$	-		$	1.51
Weighted Average Common Shares Outstanding
Basic		200.0			-			200.0
Diluted		202.4			-			202.4


⁽¹⁾ New accounting standard adjustments include a reclassication of certain costs from Selling, general and administrative expenses to Net Sales due to the adoption of ASU 2014-09 and a reclassification of certain components of pension expense from Selling, general and administrative expenses to Other expense, net due to the adoption of ASU 2017-07.

ZIMMER BIOMET HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE THREE MONTHS ENDED MARCH 31, 2017
(in millions, except per share amounts, unaudited)

	As Originally Reported			Adjustments ⁽¹⁾			As Adjusted
Net Sales	$	1,977.3		$	(4.9	)	$	1,972.4
Cost of products sold, excluding intangible asset amortization		512.9			-			512.9
Intangible asset amortization		152.0			-			152.0
Research and development		91.1			-			91.1
Selling, general and administrative		760.8			(2.6	)		758.2
Special items		110.1			-			110.1
Operating expenses		1,626.9			(2.6	)		1,624.3
Operating Profit		350.4			(2.3	)		348.1
Other expense, net		(2.8	)		2.3			(0.5	)
Interest income		0.5			-			0.5
Interest expense		(82.9	)		-			(82.9	)
Earnings before income taxes		265.2			-			265.2
Provision for income taxes		(34.1	)		-			(34.1	)
Net Earnings		299.3			-			299.3
Less: Net Loss attributable to noncontrolling interest		(0.1	)		-			(0.1	)
Net Earnings of Zimmer Biomet Holdings, Inc.	$	299.4		$	-		$	299.4

Earnings Per Common Share
Basic	$	1.49		$	-		$	1.49
Diluted	$	1.47		$	-		$	1.47

Weighted Average Common Shares Outstanding
Basic		201.1			-			201.1
Diluted		203.1			-			203.1


⁽¹⁾ New accounting standard adjustments include a reclassication of certain costs from Selling, general and administrative expenses to Net Sales due to the adoption of ASU 2014-09 and a reclassification of certain components of pension expense from Selling, general and administrative expenses to Other expense, net due to the adoption of ASU 2017-07.

ZIMMER BIOMET HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE THREE MONTHS ENDED JUNE 30, 2017
(in millions, except per share amounts, unaudited)

	As Originally Reported			Adjustments ⁽¹⁾			As Adjusted
Net Sales	$	1,954.4		$	(4.9	)	$	1,949.5
Cost of products sold, excluding intangible asset amortization		527.7			-			527.7
Intangible asset amortization		147.7			-			147.7
Research and development		90.1			-			90.1
Selling, general and administrative		748.0			(2.7	)		745.3
Special items		158.6			-			158.6
Operating expenses		1,672.1			(2.7	)		1,669.4
Operating Profit		282.3			(2.2	)		280.1
Other expense, net		(3.9	)		2.2			(1.7	)
Interest income		0.3			-			0.3
Interest expense		(82.3	)		-			(82.3	)
Earnings before income taxes		196.4			-			196.4
Provision for income taxes		12.3			-			12.3
Net Earnings		184.1			-			184.1
Less: Net Loss attributable to noncontrolling interest		(0.1	)		-			(0.1	)
Net Earnings of Zimmer Biomet Holdings, Inc.	$	184.2		$	-		$	184.2

Earnings Per Common Share
Basic	$	0.91		$	-		$	0.91
Diluted	$	0.90		$	-		$	0.90
Weighted Average Common Shares Outstanding
Basic		201.8			-			201.8
Diluted		203.7			-			203.7


⁽¹⁾ New accounting standard adjustments include a reclassication of certain costs from Selling, general and administrative expenses to Net Sales due to the adoption of ASU 2014-09 and a reclassification of certain components of pension expense from Selling, general and administrative expenses to Other expense, net due to the adoption of ASU 2017-07.

ZIMMER BIOMET HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2017
(in millions, except per share amounts, unaudited)

	As Originally Reported			Adjustments ⁽¹⁾			As Adjusted
Net Sales	$	1,818.1		$	(5.0	)	$	1,813.1
Cost of products sold, excluding intangible asset amortization		500.9			-			500.9
Intangible asset amortization		152.7			-			152.7
Research and development		91.2			-			91.2
Selling, general and administrative		694.5			(2.8	)		691.7
Goodwill impairment		32.7			-			32.7
Special items		132.7			-			132.7
Operating expenses		1,604.7			(2.8	)		1,601.9
Operating Profit		213.4			(2.2	)		211.2
Other expense, net		(4.5	)		2.2			(2.3	)
Interest income		0.6			-			0.6
Interest expense		(82.3	)		-			(82.3	)
Earnings before income taxes		127.2			-			127.2
Provision for income taxes		28.4			-			28.4
Net Earnings		98.8			-			98.8
Less: Net Loss attributable to noncontrolling interest		-			-			-
Net Earnings of Zimmer Biomet Holdings, Inc.	$	98.8		$	-		$	98.8

Earnings Per Common Share
Basic	$	0.49		$	-		$	0.49
Diluted	$	0.48		$	-		$	0.48
Weighted Average Common Shares Outstanding
Basic		202.3			-			202.3
Diluted		204.0			-			204.0


⁽¹⁾ New accounting standard adjustments include a reclassication of certain costs from Selling, general and administrative expenses to Net Sales due to the adoption of ASU 2014-09 and a reclassification of certain components of pension expense from Selling, general and administrative expenses to Other expense, net due to the adoption of ASU 2017-07.

ZIMMER BIOMET HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE THREE MONTHS ENDED DECEMBER 31, 2017
(in millions, except per share amounts, unaudited)

	As Originally Reported			Adjustments ⁽¹⁾			As Adjusted
Net Sales	$	2,074.3		$	(6.0	)	$	2,068.3
Cost of products sold, excluding intangible asset amortization		591.4			-			591.4
Intangible asset amortization		151.5			-			151.5
Research and development		95.0			-			95.0
Selling, general and administrative		770.6			(3.8	)		766.8
Goodwill impairment		272.0			-			272.0
Special items		231.7			-			231.7
Operating expenses		2,112.2			(3.8	)		2,108.4
Operating Profit		(37.9	)		(2.2	)		(40.1	)
Other expense, net		(7.1	)		2.2			(4.9	)
Interest income		0.8			-			0.8
Interest expense		(80.0	)		-			(80.0	)
Earnings before income taxes		(124.2	)		-			(124.2	)
Provision for income taxes		(1,355.4	)		-			(1,355.4	)
Net Earnings		1,231.2			-			1,231.2
Less: Net Loss attributable to noncontrolling interest		(0.2	)		-			(0.2	)
Net Earnings of Zimmer Biomet Holdings, Inc.	$	1,231.4		$	-		$	1,231.4

Earnings Per Common Share
Basic	$	6.08		$	-		$	6.08
Diluted	$	6.03		$	-		$	6.03
Weighted Average Common Shares Outstanding
Basic		202.5			-			202.5
Diluted		204.1			-			204.1


⁽¹⁾ New accounting standard adjustments include a reclassication of certain costs from Selling, general and administrative expenses to Net Sales due to the adoption of ASU 2014-09 and a reclassification of certain components of pension expense from Selling, general and administrative expenses to Other expense, net due to the adoption of ASU 2017-07.

ZIMMER BIOMET HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE YEAR ENDED DECEMBER 31, 2017
(in millions, except per share amounts, unaudited)

	As Originally Reported			Adjustments ⁽¹⁾			As Adjusted
Net Sales	$	7,824.1		$	(20.8	)	$	7,803.3
Cost of products sold, excluding intangible asset amortization		2,132.9			-			2,132.9
Intangible asset amortization		603.9			-			603.9
Research and development		367.4			-			367.4
Selling, general and administrative		2,973.9			(11.9	)		2,962.0
Goodwill impairment		304.7			-			304.7
Special items		633.1			-			633.1
Operating expenses		7,015.9			(11.9	)		7,004.0
Operating Profit		808.2			(8.9	)		799.3
Other expense, net		(18.3	)		8.9			(9.4	)
Interest income		2.2			-			2.2
Interest expense		(327.5	)		-			(327.5	)
Earnings before income taxes		464.6			-			464.6
Provision for income taxes		(1,348.8	)		-			(1,348.8	)
Net Earnings		1,813.4			-			1,813.4
Less: Net Loss attributable to noncontrolling interest		(0.4	)		-			(0.4	)
Net Earnings of Zimmer Biomet Holdings, Inc.	$	1,813.8		$	-		$	1,813.8

Earnings Per Common Share
Basic	$	8.98		$	-		$	8.98
Diluted	$	8.90		$	-		$	8.90
Weighted Average Common Shares Outstanding
Basic		201.9			-			201.9
Diluted		203.7			-			203.7



⁽¹⁾ New accounting standard adjustments include a reclassication of certain costs from Selling, general and administrative expenses to Net Sales due to the adoption of ASU 2014-09 and a reclassification of certain components of pension expense from Selling, general and administrative expenses to Other expense, net due to the adoption of ASU 2017-07.

ZIMMER BIOMET HOLDINGS, INC.
NET SALES
FOR THE THREE MONTHS ENDED MARCH 31, 2016
(in millions, unaudited)

	As Originally Reported		Adjustments ⁽¹⁾			As Adjusted
Geographic Results
Americas	$	1,177.2	$	(3.2	)	$	1,174.0
EMEA		456.3		-			456.3
Asia Pacific		270.5		-			270.5
Total	$	1,904.0	$	(3.2	)	$	1,900.8

Product Categories
Knees
Americas	$	430.2	$	(1.1	)	$	429.1
EMEA		174.0		-			174.0
Asia Pacific		99.9		-			99.9
Total		704.1		(1.1	)		703.0
Hips
Americas	$	245.2	$	(0.7	)	$	244.5
EMEA		136.7		-			136.7
Asia Pacific		85.1		-			85.1
Total		467.0		(0.7	)		466.3
S.E.T.⁽²⁾		401.0		(1.1	)		399.9
Dental		108.6		-			108.6
Spine & CMF		141.2		-			141.2
Other		82.1		(0.3	)		81.8
Total	$	1,904.0	$	(3.2	)	$	1,900.8


⁽¹⁾New accounting standard adjustments include a reclassification of certain costs from Selling, general and administrative expenses to Net Sales due to the adoption of ASU 2014-09.
⁽²⁾Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma

ZIMMER BIOMET HOLDINGS, INC.
NET SALES
FOR THE THREE MONTHS ENDED JUNE 30, 2016
(in millions, unaudited)

	As Originally Reported		Adjustments ⁽¹⁾			As Adjusted
Geographic Results
Americas	$	1,181.0	$	(3.9	)	$	1,177.1
EMEA		460.9		-			460.9
Asia Pacific		292.1		-			292.1
Total	$	1,934.0	$	(3.9	)	$	1,930.1

Product Categories
Knees
Americas	$	417.9	$	(1.1	)	$	416.8
EMEA		168.8		-			168.8
Asia Pacific		111.1		-			111.1
Total		697.8		(1.1	)		696.7
Hips
Americas	$	247.9	$	(0.6	)	$	247.3
EMEA		138.7		-			138.7
Asia Pacific		89.8		-			89.8
Total		476.4		(0.6	)		475.8
S.E.T.⁽²⁾		412.2		(1.4	)		410.8
Dental		118.0		-			118.0
Spine & CMF		145.8		(0.4	)		145.4
Other		83.8		(0.4	)		83.4
Total	$	1,934.0	$	(3.9	)	$	1,930.1


⁽¹⁾New accounting standard adjustments include a reclassification of certain costs from Selling, general and administrative expenses to Net Sales due to the adoption of ASU 2014-09.
⁽²⁾Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma

ZIMMER BIOMET HOLDINGS, INC.
NET SALES
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2016
(in millions, unaudited)

	As Originally Reported		Adjustments ⁽¹⁾			As Adjusted
Geographic Results
Americas	$	1,175.9	$	(3.6	)	$	1,172.3
EMEA		368.8		-			368.8
Asia Pacific		288.1		-			288.1
Total	$	1,832.8	$	(3.6	)	$	1,829.2

Product Categories
Knees
Americas	$	398.2	$	(1.2	)	$	397.0
EMEA		130.3		-			130.3
Asia Pacific		103.9		-			103.9
Total		632.4		(1.2	)		631.2
Hips
Americas	$	238.3	$	(0.7	)	$	237.6
EMEA		112.1		-			112.1
Asia Pacific		89.3		-			89.3
Total		439.7		(0.7	)		439.0
S.E.T.⁽²⁾		401.8		(1.3	)		400.5
Dental		95.9		-			95.9
Spine & CMF		183.7		(0.1	)		183.6
Other		79.3		(0.3	)		79.0
Total	$	1,832.8	$	(3.6	)	$	1,829.2


⁽¹⁾New accounting standard adjustments include a reclassification of certain costs from Selling, general and administrative expenses to Net Sales due to the adoption of ASU 2014-09.
⁽²⁾Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma

ZIMMER BIOMET HOLDINGS, INC.
NET SALES
FOR THE THREE MONTHS ENDED DECEMBER 31, 2016
(in millions, unaudited)

	As Originally Reported		Adjustments ⁽¹⁾			As Adjusted
Geographic Results
Americas	$	1,268.1	$	(4.8	)	$	1,263.3
EMEA		444.4		-			444.4
Asia Pacific		300.6		-			300.6
Total	$	2,013.1	$	(4.8	)	$	2,008.3

Product Categories
Knees
Americas	$	445.1	$	(1.5	)	$	443.6
EMEA		165.0		-			165.0
Asia Pacific		111.7		-			111.7
Total		721.8		(1.5	)		720.3
Hips
Americas	$	253.3	$	(0.6	)	$	252.7
EMEA		134.6		-			134.6
Asia Pacific		93.4		-			93.4
Total		481.3		(0.6	)		480.7
S.E.T.⁽²⁾		429.4		(1.5	)		427.9
Dental		105.4		-			105.4
Spine & CMF		191.3		(0.8	)		190.5
Other		83.9		(0.4	)		83.5
Total	$	2,013.1	$	(4.8	)	$	2,008.3


⁽¹⁾New accounting standard adjustments include a reclassification of certain costs from Selling, general and administrative expenses to Net Sales due to the adoption of ASU 2014-09.
⁽²⁾Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma

ZIMMER BIOMET HOLDINGS, INC.
NET SALES
FOR THE YEAR ENDED DECEMBER 31, 2016
(in millions, unaudited)

	As Originally Reported		Adjustments ⁽¹⁾			As Adjusted
Geographic Results
Americas	$	4,802.2	$	(15.5	)	$	4,786.7
EMEA		1,730.4		-			1,730.4
Asia Pacific		1,151.3		-			1,151.3
Total	$	7,683.9	$	(15.5	)	$	7,668.4

Product Categories
Knees
Americas	$	1,691.4	$	(4.9	)	$	1,686.5
EMEA		638.1		-			638.1
Asia Pacific		426.6		-			426.6
Total		2,756.1		(4.9	)		2,751.2
Hips
Americas	$	984.7	$	(2.6	)	$	982.1
EMEA		522.1		-			522.1
Asia Pacific		357.6		-			357.6
Total		1,864.4		(2.6	)		1,861.8
S.E.T.⁽²⁾		1,644.4		(5.3	)		1,639.1
Dental		427.9		-			427.9
Spine & CMF		662.0		(1.3	)		660.7
Other		329.1		(1.4	)		327.7
Total	$	7,683.9	$	(15.5	)	$	7,668.4


⁽¹⁾New accounting standard adjustments include a reclassification of certain costs from Selling, general and administrative expenses to Net Sales due to the adoption of ASU 2014-09.
⁽²⁾Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma

ZIMMER BIOMET HOLDINGS, INC.
NET SALES
FOR THE THREE MONTHS ENDED MARCH 31, 2017
(in millions, unaudited)

	As Originally Reported		Adjustments ⁽¹⁾			As Adjusted
Geographic Results
Americas	$	1,234.8	$	(4.9	)	$	1,229.9
EMEA		453.2		-			453.2
Asia Pacific		289.3		-			289.3
Total	$	1,977.3	$	(4.9	)	$	1,972.4

Product Categories
Knees
Americas	$	429.9	$	(1.9	)	$	428.0
EMEA		167.9		-			167.9
Asia Pacific		104.9		-			104.9
Total		702.7		(1.9	)		700.8
Hips
Americas	$	245.5	$	(1.0	)	$	244.5
EMEA		136.2		-			136.2
Asia Pacific		93.1		-			93.1
Total		474.8		(1.0	)		473.8
S.E.T.⁽²⁾		425.1		(1.6	)		423.5
Dental		107.8		-			107.8
Spine & CMF		186.3		-			186.3
Other		80.6		(0.4	)		80.2
Total	$	1,977.3	$	(4.9	)	$	1,972.4


⁽¹⁾New accounting standard adjustments include a reclassification of certain costs from Selling, general and administrative expenses to Net Sales due to the adoption of ASU 2014-09.
⁽²⁾Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma

ZIMMER BIOMET HOLDINGS, INC.
NET SALES
FOR THE THREE MONTHS ENDED JUNE 30, 2017
(in millions, unaudited)

	As Originally Reported		Adjustments ⁽¹⁾			As Adjusted
Geographic Results
Americas	$	1,208.8	$	(4.9	)	$	1,203.9
EMEA		438.2		-			438.2
Asia Pacific		307.4		-			307.4
Total	$	1,954.4	$	(4.9	)	$	1,949.5

Product Categories
Knees
Americas	$	406.8	$	(1.4	)	$	405.4
EMEA		159.8		-			159.8
Asia Pacific		114.8		-			114.8
Total		681.4		(1.4	)		680.0
Hips
Americas	$	244.2	$	(0.8	)	$	243.4
EMEA		130.7		-			130.7
Asia Pacific		93.9		-			93.9
Total		468.8		(0.8	)		468.0
S.E.T.⁽²⁾		422.8		(1.7	)		421.1
Dental		110.4		-			110.4
Spine & CMF		194.0		(0.7	)		193.3
Other		77.0		(0.3	)		76.7
Total	$	1,954.4	$	(4.9	)	$	1,949.5


⁽¹⁾New accounting standard adjustments include a reclassification of certain costs from Selling, general and administrative expenses to Net Sales due to the adoption of ASU 2014-09.
⁽²⁾Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma

ZIMMER BIOMET HOLDINGS, INC.
NET SALES
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2017
(in millions, unaudited)

	As Originally Reported		Adjustments ⁽¹⁾			As Adjusted
Geographic Results
Americas	$	1,142.0	$	(5.0	)	$	1,137.0
EMEA		381.1		-			381.1
Asia Pacific		295.0		-			295.0
Total	$	1,818.1	$	(5.0	)	$	1,813.1

Product Categories
Knees
Americas	$	383.2	$	(1.7	)	$	381.5
EMEA		135.1		-			135.1
Asia Pacific		106.3		-			106.3
Total		624.6		(1.7	)		622.9
Hips
Americas	$	227.4	$	(0.8	)	$	226.6
EMEA		115.1		-			115.1
Asia Pacific		91.1		-			91.1
Total		433.6		(0.8	)		432.8
S.E.T.⁽²⁾		406.6		(1.8	)		404.8
Dental		92.9		-			92.9
Spine & CMF		184.9		(0.4	)		184.5
Other		75.5		(0.3	)		75.2
Total	$	1,818.1	$	(5.0	)	$	1,813.1


⁽¹⁾New accounting standard adjustments include a reclassification of certain costs from Selling, general and administrative expenses to Net Sales due to the adoption of ASU 2014-09.
⁽²⁾Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma

ZIMMER BIOMET HOLDINGS, INC.
NET SALES
FOR THE THREE MONTHS ENDED DECEMBER 31, 2017
(in millions, unaudited)

	As Originally Reported		Adjustments ⁽¹⁾			As Adjusted
Geographic Results
Americas	$	1,280.0	$	(6.0	)	$	1,274.0
EMEA		472.7		-			472.7
Asia Pacific		321.6		-			321.6
Total	$	2,074.3	$	(6.0	)	$	2,068.3

Product Categories
Knees
Americas	$	443.4	$	(1.8	)	$	441.6
EMEA		181.6		-			181.6
Asia Pacific		107.1		-			107.1
Total		732.1		(1.8	)		730.3
Hips
Americas	$	255.4	$	(1.0	)	$	254.4
EMEA		136.4		-			136.4
Asia Pacific		106.4		-			106.4
Total		498.2		(1.0	)		497.2
S.E.T.⁽²⁾		454.6		(2.2	)		452.4
Dental		107.5		-			107.5
Spine & CMF		194.3		(0.5	)		193.8
Other		87.6		(0.5	)		87.1
Total	$	2,074.3	$	(6.0	)	$	2,068.3


⁽¹⁾New accounting standard adjustments include a reclassification of certain costs from Selling, general and administrative expenses to Net Sales due to the adoption of ASU 2014-09.
⁽²⁾Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma

ZIMMER BIOMET HOLDINGS, INC.
NET SALES
FOR THE YEAR ENDED DECEMBER 31, 2017
(in millions, unaudited)

	As Originally Reported		Adjustments ⁽¹⁾			As Adjusted
Geographic Results
Americas	$	4,865.6	$	(20.8	)	$	4,844.8
EMEA		1,745.2		-			1,745.2
Asia Pacific		1,213.3		-			1,213.3
Total	$	7,824.1	$	(20.8	)	$	7,803.3

Product Categories
Knees
Americas	$	1,663.3	$	(6.8	)	$	1,656.5
EMEA		644.4		-			644.4
Asia Pacific		433.1		-			433.1
Total		2,740.8		(6.8	)		2,734.0
Hips
Americas	$	972.5	$	(3.6	)	$	968.9
EMEA		518.4		-			518.4
Asia Pacific		384.5		-			384.5
Total		1,875.4		(3.6	)		1,871.8
S.E.T.⁽²⁾		1,709.1		(7.3	)		1,701.8
Dental		418.6		-			418.6
Spine & CMF		759.5		(1.6	)		757.9
Other		320.7		(1.5	)		319.2
Total	$	7,824.1	$	(20.8	)	$	7,803.3


⁽¹⁾New accounting standard adjustments include a reclassification of certain costs from Selling, general and administrative expenses to Net Sales due to the adoption of ASU 2014-09.
⁽²⁾ Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma

ZIMMER BIOMET HOLDINGS, INC.
Reconciliation of Revised Gross Profit & Margin to Adjusted Gross Profit & Margin
For the Quarterly and Full Year Periods in Calendar Year Ended December 31, 2017
(in millions, unaudited)

	Three Months Ended			Three Months Ended			Three Months Ended			Three Months Ended			Year Ended
	March 31, 2017			June 30, 2017			September 30, 2017			December 31, 2017			December 31, 2017
Revised⁽¹⁾ Net Sales	$	1,972.4		$	1,949.5		$	1,813.1		$	2,068.3		$	7,803.3
Cost of products sold, excluding intangible asset amortization		512.9			527.7			500.9			591.4			2,132.9
Intangible asset amortization		152.0			147.7			152.7			151.5			603.9
Revised⁽¹⁾ Gross profit	$	1,307.5		$	1,274.1		$	1,159.5		$	1,325.4		$	5,066.5
Inventory step-up and other inventory and manufacturing related charges		23.2			24.9			10.4			26.1			84.6
Intangible asset amortization		152.0			147.7			152.7			151.5			603.9
Adjusted gross profit	$	1,482.7		$	1,446.7		$	1,322.6		$	1,503.0		$	5,755.0

Revised⁽¹⁾ Gross margin		66.3	%		65.4	%		64.0	%		64.1	%		64.9	%
Inventory step-up and other inventory and manufacturing related charges		1.2			1.2			0.5			1.3			1.2
Intangible asset amortization		7.7			7.6			8.4			7.3			7.7
Adjusted gross margin		75.2	%		74.2	%		72.9	%		72.7	%		73.8	%

⁽¹⁾ Revisions resulting from adoption of ASU 2014-09

ZIMMER BIOMET HOLDINGS, INC.
Reconciliation of Revised Gross Profit & Margin to Adjusted Gross Profit & Margin
For the Quarterly and Full Year Periods in Calendar Year Ended December 31, 2016
(in millions, unaudited)

	Three Months Ended			Three Months Ended			Three Months Ended			Three Months Ended			Year Ended
	March 31, 2016			June 30, 2016			September 30, 2016			December 31, 2016			December 31, 2016
Revised⁽¹⁾ Net Sales	$	1,900.8		$	1,930.1		$	1,829.2		$	2,008.3		$	7,668.4
Cost of products sold, excluding intangible asset amortization		640.6			640.1			479.3			621.8			2,381.8
Intangible asset amortization		126.6			133.8			164.3			141.2			565.9
Revised⁽¹⁾ Gross profit	$	1,133.6		$	1,156.2		$	1,185.6		$	1,245.3		$	4,720.7
Inventory step-up and other inventory and manufacturing related charges		178.3			156.6			22.8			111.4			469.1
Intangible asset amortization		126.6			133.8			164.3			141.2			565.9
Adjusted gross profit	$	1,438.5		$	1,446.6		$	1,372.7		$	1,497.9		$	5,755.7

Revised⁽¹⁾ Gross margin		59.6	%		59.9	%		64.8	%		62.0	%		61.6	%
Inventory step-up and other inventory and manufacturing related charges		9.4			8.1			1.2			5.6			6.1
Intangible asset amortization		6.7			6.9			9.0			7.0			7.4
Adjusted gross margin		75.7	%		74.9	%		75.0	%		74.6	%		75.1	%

⁽¹⁾ Revisions resulting from adoption of ASU 2014-09

ZIMMER BIOMET HOLDINGS, INC.
Reconciliation of Revised Operating Profit (Loss) & Margin to Adjusted Operating Profit & Margin
For the Quarterly and Full Year Periods in Calendar Year Ended December 31, 2017
(in millions, unaudited)

	Three Months Ended			Three Months Ended			Three Months Ended			Three Months Ended			Year Ended
	March 31, 2017			June 30, 2017			September 30, 2017			December 31, 2017			December 31, 2017
Revised⁽¹⁾ Operating profit (loss)	$	348.1		$	280.1		$	211.2		$	(40.1	)	$	799.3
Inventory step-up and other inventory and manufacturing related charges		23.2			24.9			10.4			26.1			84.6
Intangible asset amortization		152.0			147.7			152.7			151.5			603.9
Goodwill impairment		-			-			32.7			272.0			304.7
Special items		110.1			158.6			132.7			231.7			633.1
Adjusted operating profit	$	633.4		$	611.3		$	539.7		$	641.2		$	2,425.6

Revised⁽¹⁾ Operating profit (loss) margin		17.7	%		14.4	%		11.7	%		(1.9	)%		10.2	%
Inventory step-up and other inventory and manufacturing related charges		1.2			1.2			0.5			1.3			1.2
Intangible asset amortization		7.7			7.6			8.4			7.3			7.7
Goodwill impairment		-			-			1.8			13.2			3.9
Special items		5.5			8.2			7.4			11.1			8.1
Adjusted operating profit margin		32.1	%		31.4	%		29.8	%		31.0	%		31.1	%

⁽¹⁾ Revisions resulting from adoption of ASU 2014-09 and ASU 2017-07

ZIMMER BIOMET HOLDINGS, INC.
Reconciliation of Operating Profit & Margin to Adjusted Operating Profit & Margin
For the Quarterly and Full Year Periods in Calendar Year Ended December 31, 2016
(in millions, unaudited)

	Three Months Ended			Three Months Ended			Three Months Ended			Three Months Ended			Year Ended
	March 31, 2016			June 30, 2016			September 30, 2016			December 31, 2016			December 31, 2016
Revised⁽¹⁾ Operating profit	$	244.3		$	200.4		$	194.3		$	182.1		$	821.1
Inventory step-up and other inventory and manufacturing related charges		178.3			156.6			22.8			111.4			469.1
Intangible asset amortization		126.6			133.8			164.3			141.2			565.9
Special items		88.7			137.9			170.4			214.8			611.8
Adjusted operating profit	$	637.9		$	628.7		$	551.8		$	649.5		$	2,467.9

Revised⁽¹⁾ Operating profit margin		12.9	%		10.4	%		10.6	%		9.1	%		10.7	%
Inventory step-up and other inventory and manufacturing related charges		9.4			8.1			1.2			5.6			6.1
Intangible asset amortization		6.7			6.9			9.0			7.0			7.4
Special items		4.6			7.2			9.4			10.6			8.0
Adjusted operating profit margin		33.6	%		32.6	%		30.2	%		32.3	%		32.2	%

⁽¹⁾ Revisions resulting from adoption of ASU 2014-09 and ASU 2017-07

GRAPHIC 3 g201804061944318267037.jpg GRAPHIC begin 644 g201804061944318267037.jpg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end